A study was launched in the years following World War II, researchers set out to understand what actually drives cardiovascular disease. They recruited 5,209 residents from Framingham between the ages of 30 and 62 and followed them over time. Back then, the medical community had only a vague idea of what counted as a real risk. High blood pressure was considered “not great,” but the thresholds were wildly off by today’s standards. Values that would now be treated as a medical emergency were once seen as normal. In simple terms, they were operating with very little clarity.
When the first results came out in 1957, things started to change. The researchers identified three major risk factors for cardiovascular disease: high blood pressure, obesity, and high cholesterol. Their definition of hypertension began to look more like what we recognize today, but the real shift came from linking elevated cholesterol to heart disease. That discovery opened the door to decades of research into blood lipids and how they influence long term health.
Most of that research has focused on markers like total cholesterol, LDL, HDL, ApoB, ApoA1, and lipoprotein(a). Among these, LDL and HDL are the ones most people already know. LDL is typically labeled as the “bad” cholesterol because higher levels are directly tied to increased cardiovascular risk. HDL gets called the “good” cholesterol since higher levels are generally associated with lower risk. Unlike HDL, the role of LDL is not just a correlation. It is a confirmed cause, which is why lowering LDL is a central goal in managing cardiovascular health. This is where statins come in, working by blocking cholesterol production in the liver and reducing overall LDL levels.
When it comes to anabolic steroids, their impact on these markers is mixed but leans negative. Controlled studies show that testosterone, even at higher doses, tends to have a relatively mild effect on LDL but can reduce HDL over time, especially at higher doses or longer durations. That drop in HDL appears to be dose dependent, meaning the more you take, the more it tends to fall. Exercise may offset some of this, but not completely.
Other compounds paint a worse picture. Oral steroids like stanozolol can significantly crush HDL levels while increasing LDL, creating a much more unfavorable profile. Even at relatively low doses, the shift can be dramatic, especially in the HDL subfractions that may matter most for heart health. Nandrolone tends to fall somewhere in between, with smaller or inconsistent effects depending on the study.
One key mechanism behind the drop in HDL is increased activity of hepatic lipase, an enzyme that breaks down larger, more protective HDL particles into smaller ones that are cleared more easily from the bloodstream. Over time, this leads to a net reduction in HDL levels.
What makes this more complicated is that simply changing HDL numbers does not always translate directly to changes in disease risk. Newer research is looking beyond HDL levels and focusing on how well HDL actually functions, especially its ability to remove cholesterol from artery walls. This process, known as cholesterol efflux, may be a more meaningful indicator of cardiovascular protection.
There is some evidence suggesting long term anabolic steroid use may impair this function, but the data is limited and not definitive. Some controlled trials show no change, while observational data in heavy users suggests a decline. The reality is that we still do not have a clear answer on how these changes in HDL function translate into real world cardiovascular outcomes.
Looking beyond LDL and HDL, apolipoproteins add another layer. ApoB reflects the number of LDL particles in circulation and may be an even stronger predictor of cardiovascular risk than LDL cholesterol itself. ApoA1 is tied to HDL and plays a role in its protective functions. While these markers can provide deeper insight, they are not yet widely used as primary treatment targets.
Lipoprotein(a), or Lp(a), is another factor worth mentioning. It behaves similarly to LDL in promoting plaque buildup, but anabolic steroids may actually lower its levels in some cases. While that sounds like a positive, it does not cancel out the broader negative shifts seen in other lipid markers.
Anabolic steroids consistently push blood lipids in the wrong direction, even if the degree varies by compound, dose, and duration. Some effects are mild, others are aggressive, and a few may even look beneficial in isolation. However, the overall pattern points toward increased cardiovascular strain, even if the exact level of risk is still being worked out.